Thermostable FGF2 Variants for Embryonic Stem Cell Culture

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Fibroblast Growth Factor-2 (FGF2) has a short half-life in culture media, requiring daily supplementation in human embryonic stem cell cultures, which is costly and inefficient, especially in large-scale production for therapeutics.

Innovation Solution

Engineered FGF2 variants with increased thermostability, such as those with amino acid substitutions like Q65I, N111G, and C96S, are developed to maintain embryonic stem cells in an undifferentiated state for extended periods without the need for frequent supplementation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If wild-type FGF2 is used in embryonic stem cell culture media, then the cells are maintained in an undifferentiated state, but the FGF2 has a short half-life requiring daily supplementation

Engineering Contradiction:

Improvehalf-life of FGF2 in culture mediaVSAvoidfrequency of supplementation required

Core Design Contradiction:

Duration of action of moving objectVSLoss of time

Solution Approach 1:

The patent applies parameter changes by modifying the amino acid sequence of FGF2 through site-directed mutagenesis. Specific residues (Q65, N111, C96) are mutated to improve thermostability and extend the half-life of the growth factor in culture media, directly addressing the short duration of action without requiring frequent supplementation

Inventive Principle:

Principle #35Parameter changes

2Reliability

If daily supplementation of FGF2 is performed to maintain effective concentration, then the undifferentiated state is maintained, but the cost and labor increase significantly

Engineering Contradiction:

Improvemaintenance of undifferentiated stateVSAvoidcost and labor efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent modifies the biochemical parameters of FGF2 by introducing amino acid substitutions that enhance thermostability and resistance to degradation. This extends the functional duration of the growth factor, reducing the frequency of supplementation needed and thereby lowering operational costs and labor requirements while maintaining reliable undifferentiated state maintenance

Inventive Principle:

Principle #35Parameter changes

3Reliability

If high concentrations of FGF2 are used to compensate for rapid degradation, then the undifferentiated state is maintained, but the cost of culture media increases

Engineering Contradiction:

Improvemaintenance of undifferentiated stateVSAvoidconcentration of FGF2 required

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent changes the structural parameters of FGF2 through amino acid mutations that improve stability and reduce degradation rates. This allows the use of lower concentrations of the growth factor over extended periods, reducing the total quantity of FGF2 consumed and lowering the cost of culture media while maintaining effective maintenance of the undifferentiated state

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9169309B2Thermostable variants of fibroblast growth factors

Publication Date: 2015.10.27 HUMANZYME

AI summary

The present technology relates to engineered human Fibroblast Growth Factor-2 (FGF2) proteins and methods of using the same. In particular, the methods and compositions relate to FGF2 mutants with increased thermostability compared to the wild-type protein and method for using the proteins in the culturing of embryonic stem cells.